Director

Chris Kiritsy

Mr. Kiritsy is founder and managing member of Precision Kapital, LLC, a private investment and advisory firm. Prior to forming Precision Kapital, Mr. Kiritsy teamed up with the late pharmaceutical legend, Michael Jaharis, to co-found Arisaph Pharmaceuticals and served as Arisaph’s President and Chief Executive Officer from 2005 through 2018. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from start-up to highly profitable, publicly traded, commercial company, in which Kos internally developed and commercialized the blockbuster Niaspan® franchise. Mr. Kiritsy spearheaded more than 10 major corporate development transactions and raised approximately $500 million in public equity, including Kos’ initial public offering. Kos was acquired by Abbott Laboratories for $3.7 billion in 2016. Additionally, Mr. Kiritsy has broad corporate governance experience, previously serving as board member and various committee chairs of multiple public and private companies. Mr. Kiritsy also serves as an advisor to Red Sky Partners, LLC. Mr. Kiritsy is a seasoned entrepreneur, who possesses 30 years of industry experience, building emerging biopharmaceutical companies with expertise in R&D, business development and finance.